Quality problems scupper Daiichi Sankyo's flu vaccine plans
This article was originally published in Scrip
Executive Summary
Daiichi Sankyo is unable to ship at least half of the originally planned output of an influenza vaccine produced by a joint venture in Japan due to quality problems, and is carrying out tests on remaining batches which could further increase the shortfall.